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3As the World Drug Report 2017 clearly shows, there 
is much work to be done to confront the many 
harms inflicted by drugs, to health, development, 
peace and security, in all regions of the world.
Globally, there are an estimated minimum of 
190,000 — in most cases avoidable — premature 
deaths from drugs, the majority attributable to the 
use of opioids.
The terrible impact of drug use on health can also 
be seen in related cases of HIV, hepatitis and 
tuberculosis. 
Much more needs to be done to ensure affordable 
access to effective scientific evidence-based preven-
tion, treatment and care for the people who 
desperately need them, including those in prison 
settings. As just one example, this year’s report high-
lights the need to accelerate accessibility to the 
treatment of hepatitis C, a disease whose negative 
health impact on people who use drugs is far greater 
than that of HIV/AIDS.  
Recent attention has focused on the threats posed 
by methamphetamine and new psychoactive sub-
stances (NPS). However, as the report shows, the 
manufacture of both cocaine and opioids is increas-
ing. These drugs remain serious concerns, and the 
opioid crisis shows little sign of stopping. 
The World Drug Report 2017 further looks at the 
links with other forms of organized crime, illicit 
financial flows, corruption and terrorism. It draws 
on the best available evidence and, most of all, high-
lights the fact that much more research needs to be 
carried out in these areas. 
Corruption is the great enabler of organized crime, 
and opportunities for corruption exist at every stage 
of the drug supply chain. However, too little is 
known about how different types of corruption 
interact with drug markets. 
The outcome document of the special session of the 
General Assembly on the world drug problem and 
I am proud to say that this year we are marking 20 
years of the World Drug Report.
Over the past two decades, the United Nations 
Office on Drugs and Crime (UNODC) has been 
at the forefront of global research into complex areas 
of drug use and supply, supporting international 
cooperation and informing policy choices with the 
latest estimates, information on trends and 
analysis.
This year we are launching a new format, with the 
report available as five separate booklets: the execu-
tive summary, together with the report’s conclusions 
and policy implications; a global overview of drug 
use and supply; a market analysis of plant-based 
drugs; a market analysis of synthetic drugs; and a 
thematic booklet on the links between drugs and 
organized crime, illicit financial flows, corruption 
and terrorism. We have done this in response to 
readers’ needs and to improve user-friendliness, 
while maintaining the rigorous standards expected 
from the Office’s flagship publication. 
The 2017 report comes at a time when the interna-
tional community has acted decisively to achieve 
consensus on a way forward for joint action.
The outcome document unanimously adopted at 
last year’s special session of the General Assembly 
on the world drug problem contains more than 100 
concrete recommendations for implementing bal-
anced, comprehensive and integrated approaches to 
effectively addressing and countering the world drug 
problem. 
Moreover, at its sixtieth session, in March 2017, the 
Commission on Narcotic Drugs adopted resolution 
60/1, reinforcing commitment to implementing the 
outcome document and charting a course to the 
2019 target date of the 2009 Political Declaration 
and Plan of Action on the world drug problem, as 
well as strengthening action towards the Plan of 
Action’s agreed goals and targets. 
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As the special session of the General Assembly and 
the recent session of the Commission on Narcotic 
Drugs have shown, the international community is 
equipped to respond swiftly and decisively to global 
drug-related challenges. 
For example, in March, the Commission scheduled 
two precursors and an analogue to the scheduled 
drug fentanyl. This important step will make it 
harder for criminals to illicitly manufacture fentanyl 
and its analogues and, I hope, can help to stem the 
tragic increase in opioid overdoses in recent years. 
However, there remains an enormous need for 
capacity-building and technical assistance, and fund-
ing continues to fall far short of political 
commitment. Further resources are urgently needed 
to help all Member States implement the recom-
mendations contained in the outcome document 
of the special session of the General Assembly and 
achieve related targets under the Sustainable Devel-
opment Goals.
The many evolving drug challenges also highlight 
the importance of prevention — science- and rights-
based drug use prevention — but also prevention 
of crime, corruption, terrorism and violent extrem-
ism, in line with commitments under the 
conventions and United Nations standards and 
norms. 
Finally, I ask all Governments to help us improve 
the evidence base for these reports. Areas such as 
the links between drugs, terrorism and insurgency 
clearly touch upon sensitive intelligence, and there 
are legitimate concerns about compromising sources, 
collection and operations. But if we want to effec-
tively address drug challenges we need to strengthen 
international cooperation and information-sharing 
to the extent possible, to close the gaps and ensure 
that joint action is targeted, effective and timely. 
Yury Fedotov
Executive Director
United Nations Office on Drugs and Crime
Security Council resolutions express concern about 
terrorist groups profiting from drug trafficking, 
among other forms of transnational organized crime.
It is well established that there are terrorists and 
non-State armed groups profiting from the drug 
trade — by some estimates, up to 85 per cent of 
opium poppy cultivation in Afghanistan is in terri-
tory under influence of the Taliban. 
However, evidence on the organized crime-terrorism 
nexus remains patchy at best. Moreover, these links 
are not static. Relations between organized crime 
and terrorists groups are always evolving, much like 
drug markets themselves.
As we have seen with the NPS market, drug use, 
supply, trafficking routes and the substances them-
selves continue to shift and diversify at alarming 
speed. 
Drugs continue to represent a major source of rev-
enue for organized crime networks, but business 
models are changing, with criminals exploiting new 
technologies, such as the darknet, that are altering 
the nature of the illicit drug trade and the types of 
players involved, with looser, horizontal networks 
and smaller groups becoming more significant. New 
ways of delivering drugs further point to the need 
to involve other sectors such as postal services in the 
fight against drug trafficking.  
Clearly, countries must be able to act and react to 
an ever-changing and formidable array of threats 
and problems. UNODC is fully engaged in strength-
ening responses, working closely with our United 
Nations partners and in line with the international 
drug control conventions, human rights instruments 
and the 2030 Agenda for Sustainable Development, 
which are themselves complementary and mutually 
reinforcing.
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7EXPLANATORY NOTES 
The boundaries and names shown and the designa-
tions used on maps do not imply official endorsement 
or acceptance by the United Nations. A dotted line 
represents approximately the line of control in 
Jammu and Kashmir agreed upon by India and Paki-
stan. The final status of Jammu and Kashmir has 
not yet been agreed upon by the parties. Disputed 
boundaries (China/India) are represented by cross-
hatch owing to the difficulty of showing sufficient 
detail. 
The designations employed and the presentation of 
the material in the World Drug Report do not imply 
the expression of any opinion whatsoever on the 
part of the Secretariat of the United Nations con-
cerning the legal status of any country, territory, city 
or area, or of its authorities or concerning the delimi-
tation of its frontiers or boundaries.
Countries and areas are referred to by the names 
that were in official use at the time the relevant data 
were collected.
All references to Kosovo in the World Drug Report, 
if any, should be understood to be in compliance 
with Security Council resolution 1244 (1999).
Since there is some scientific and legal ambiguity 
about the distinctions between “drug use”, “drug 
misuse” and “drug abuse”, the neutral terms “drug 
use” and “drug consumption” are used in the World 
Drug Report.
All uses of the word “drug” in the World Drug Report 
refer to substances under the control of the inter-
national drug control conventions.
All analysis contained in the World Drug Report is 
based on the official data submitted by Member 
States to the United Nations Office on Drugs and 
Crime through the annual report questionnaire 
unless indicated otherwise.
The data on population used in the World Drug 
Report are taken from: United Nations, Department 
of Economic and Social Affairs, Population Divi-
sion, World Population Prospects: The 2015 
Revision. 
References to dollars ($) are to United States dollars, 
unless otherwise stated.
References to tons are to metric tons, unless other-
wise stated. R stands for the correlation coefficient, 
used as measure of the strength of a statistical rela-
tionship between two or more variables, ranging 
from 0 to 1 in case of a positive correlation or from 
0 to -1 in case of a negative correlation. 

9Of those years lost, 17 million were attributable 
solely to drug use disorders across all drug types. 
DALYs attributable to morbidity and mortality 
resulting from all causes of drug use have increased 
overall in the past decade. 
Yet, with fewer than one in six persons with drug 
use disorders provided with treatment each year, the 
availability of and access to science-based services 
for the treatment of drug use disorders and related 
conditions remain limited. 
Opioids, the most harmful drug type 
Opioids, including heroin, remain the most harmful 
drug type in health terms. The use of opioids is 
associated with the risk of fatal and non-fatal over-
doses; the risk of acquiring infectious diseases (such 
Harm caused by drug use remains 
considerable
An estimated quarter of a billion people, or around 
5 per cent of the global adult population, used drugs 
at least once in 2015. Even more worrisome is the 
fact that about 29.5 million of those drug users, or 
0.6 per cent of the global adult population, suffer 
from drug use disorders. This means that their drug 
use is harmful to the point that they may experience 
drug dependence and require treatment.
The magnitude of the harm caused by drug use is 
underlined by the estimated 28 million years of 
“healthy” life (disability-adjusted life years (DALYs)) 
lost worldwide in 2015 as a result of premature death 
and disability caused by drug use. 
EXECUTIVE SUMMARY
10 million years of life lost as a result of disability caused by drug use
18 million years of life lost as a result of premature death caused by drug use
17 million DALYs attributed to drug use disorders 
DALYs
attributed
to drug use
28 million healthy years of life lost as a result of drug use
17 million healthy years of life lost as a result of drug use disorders
+
years of “healthy”
 life lost as a result 
of disability
=
years of life lost as a 
result of premature 
death
drug use
disability
premature
death
years of 
life lost
birth expected 
life years
DALYs
 28 million 
“healthy” years of life lost
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alone, to reach the highest level ever recorded. 
Indeed, far more people die from the misuse of opi-
oids in the United States each year than from road 
traffic accidents or violence.
The emergence of derivatives of prescription medi-
cines, classified as new psychoactive substances 
(NPS), particularly fentanyl analogues, has been 
associated with rising numbers of overdoses, includ-
ing fatal overdoses, among opioid users. In recent 
years, several emergent synthetic opioids have been 
associated with increasing numbers of serious 
adverse events and deaths. The pills and powders 
containing synthetic opioids sold on the illicit 
market pose a threat to public health, a problem 
that is compounded by the variation in both the 
quantity and potency of their active components.
Methamphetamine accounts for  
considerable harm
Disorders related to the use of amphetamines 
account for a considerable share of the global burden 
of disease attributable to drug use disorders, second 
only to those related to the use of opioids. Available 
data show that, among amphetamines, metham-
phetamine represents the greatest global health 
threat. Methamphetamine use is spreading and an 
as HIV or hepatitis C) through unsafe injecting 
practices; and the risk of other medical and psychi-
atric co-morbidities. 
The large number of premature deaths related to 
drugs are mostly avoidable. A significant proportion 
of those deaths is attributable to opioids. In addi-
tion, opioid use disorders account for the heaviest 
burden of disease attributable to drug use disorders: 
in 2015, almost 12 million DALYs, or 70 per cent 
of the global burden of disease attributable to drug 
use disorders, were attributable to opioids.
A problem in many countries, the harm caused by 
opioids is particularly evident in the United States 
of America. The misuse of pharmaceutical opioids, 
coupled with an increase in heroin and fentanyl use, 
has resulted in a combined and interrelated epidemic 
in the United States, as well as in an increase in 
morbidity and mortality related to opioids. 
The United States accounts for approximately one 
quarter of the estimated number of drug-related 
deaths worldwide, including overdose deaths, which 
continue to rise. Mostly driven by opioids, overdose 
deaths in the United States more than tripled during 
the period 1999-2015, from 16,849 to 52,404 annu-
ally, and increased by 11.4 per cent in the past year 
183
cannabis
35
opioids
18
opiates
Number of  past-year users in  2015
17
cocaine
37
amphetamines &
 prescription stimulants
22
“ecstasy”
million million million
million millionmillion
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Hepatitis C causing greatest harm among 
people who use drugs 
Globally, the negative health consequences related 
to hepatitis C among people who use drugs are sub-
stantial. The number of deaths attributable to 
hepatitis C among people who use drugs is greater 
than from other causes of death related to drug use. 
Overall, more DALYs are lost as a result of hepatitis 
C than of HIV infection among people who use 
drugs. Most of those DALYs are the result of pre-
mature death, while the remainder are the result of 
years lived with disability. 
Recent advances in the treatment of hepatitis C, 
using direct-acting antivirals, have created a new 
opportunity to reduce the heavy burden of the dis-
ease among people who use drugs. Nevertheless, 
accessibility remains poor for many of those in need, 
as such treatment options remain very expensive in 
most countries. 
increasing number of methamphetamine users are 
seeking treatment. In addition to the established and 
expanding market for methamphetamine in East 
and South-East Asia and Oceania, there are growing 
concerns about methamphetamine use in North 
America, South-West Asia and parts of Europe. 
Cocaine use disorders increasing
Although the number of cocaine users is decreasing 
or stabilizing in parts of Europe, wastewater analysis 
suggests that cocaine consumption in that region 
may be increasing. Following several years of decline, 
there are also indications of an increase in cocaine 
use in North America. Moreover, drug overdose 
cases involving cocaine increased markedly in the 
United States between 2012 and 2015. Much of 
that increase is linked, however, to the use of cocaine 
in combination with opioids. Globally, DALYs 
attributed to cocaine use disorders increased from 
729,000 in 2005 to 999,000 in 2015.
New psychoactive substances potentially 
more lethal than other drugs, but market 
still relatively small
Despite the large number of NPS present in drug 
markets, the overall size of the market for such sub-
stances is still relatively small when compared with 
other drug markets. However, one of the most trou-
bling aspects of NPS is that users are unaware of the 
content and the dosage of the psychoactive sub-
stances contained in some NPS. This potentially 
exposes users of NPS to additional serious health 
risks. Little or no scientific information is available 
to determine the effects that these products may 
have and how best to counteract them. 
A number of NPS have been implicated in fatalities, 
while the injecting of NPS with stimulant effects 
has been reported among high-risk groups of people 
who use drugs, further aggravating the health risks 
to which people in those groups are exposed. 
Who suffers the heaviest burden of  
disease from drug use?
People who inject drugs (PWID) face some of the 
most severe health consequences associated with 
drug use. Almost 12 million people worldwide inject 
drugs, of whom one in eight (1.6 million) are living 
with HIV and more than half (6.1 million) are living 
with hepatitis C.
12 million people inject drugs
1.6 million people who inject drugs
 are living with HIV
6.1 million are living with hepatitis C
1.3 million are living with both
 hepatitis C and HIV
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People who use drugs may have a particular need 
for interventions that prevent and treat tuberculosis. 
They may be disproportionately affected by the risk 
factors for the disease (such as poverty, malnutrition, 
infection with HIV and time spent in prison). Infec-
tion with HIV is one of the main reasons for the 
high prevalence of tuberculosis among PWID and 
tuberculosis is one of the leading causes of mortality 
among people who use drugs and are living with 
HIV.
Treatment of tuberculosis is particularly complex 
for people who use drugs as they may be living with 
multiple, co-existing infectious diseases (such as 
HIV and hepatitis C) and psychiatric and medical 
co-morbidities (such as depression and anxiety) in 
addition to drug dependency. Furthermore, many 
barriers to the prevention and treatment of tuber-
culosis are more difficult to surmount for people 
who use drugs than for the general population. 
Prison a high-risk environment for the 
spread of infectious diseases
On any given day, approximately 10 million people 
are held in prison (including in pretrial detention) 
throughout the world. The number of people who 
pass through prison each year is, however, consider-
ably higher. 
People who use drugs particularly  
vulnerable to tuberculosis
Tuberculosis is more prevalent among people who 
use drugs than in the general population. Based on 
the limited data available from studies in Europe, 
Asia and the Americas, the prevalence of tubercu-
losis among PWID is estimated at approximately 8 
per cent. Meanwhile, the prevalence of tuberculosis 
in the general population at the global level is esti-
mated at less than 0.2 per cent. 
222,000 hepatitis
 C deaths
60,000 HIV 
deaths
Among people who use drugs, 
more die from hepatitis C than from HIV
drug use
0.2 million years lost as a result of disability
2.8 million years lost as a result of premature death
DALYs
attributed
to HIV
birth expected
life years
drug use
DALYs
attributed
to hepatitis C
birth expected
life years
0.1 million years lost as a result of disability
6.2 million years lost as a result of premature death
years of
life lost
years of
life lost
More years of "healthy" life lost (DALYs) as a result of 
hepatitis C than of HIV among people who use drugs
 
premature 
death
 
premature 
death
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Drug market diversification
In recent years, the spectrum of substances available 
on the drug market has widened considerably, with 
the persistence of traditional drugs and the emer-
gence of NPS every year. A characteristic of drug 
use patterns for many years, polydrug use is not a 
new phenomenon; however, it now poses an even 
greater risk because of the sheer number of sub-
stances on the market and the potential combinations 
that can be used. 
Opioid market in a constant state  
of change 
The opioid market is becoming more diversified: 
this is illustrated by the example of the United States, 
where the opioid market comprises a combination 
of internationally controlled substances, particularly 
heroin, and prescription medicines that are either 
diverted from the legal market or produced as 
counterfeit medicines on a large scale. These 
counterfeit medicines are made to look like 
pharmaceutical products while actually containing 
fentanyl and fentanyl analogues, as well as non-
opioid substances such as derivatives of 
benzodiazepine and methylphenidate. 
In many subregions, an increasingly complex rela-
tionship between the use of heroin and synthetic 
opioids is being observed. The illicit manufacture 
of opioids and the availability of numerous “research 
opioids”, which were first synthesized in the 1970s 
and have structures distinct from those used in 
Drug use, including the use of heroin and injecting 
drug use, are commonplace in many prisons. One 
out of three prisoners has used an illicit substance 
at some time while incarcerated, with 16 per cent 
reporting current (past-month) use. Cannabis is by 
far the most commonly used drug in prison, while 
heroin ranks second. Approximately 10 per cent of 
prisoners report using heroin at some time while 
incarcerated, one third of whom report current 
(past-month) use within prison. 
PWID who are incarcerated are placed in a high-
risk environment for the spread of infectious 
diseases. Unsafe injecting practices help to spread 
HIV among PWID in prison populations and ulti-
mately to the wider community. People who use 
drugs who are incarcerated are also placed at greater 
risk of tuberculosis.
Higher rate of increase in the burden of 
disease from drug use disorders among 
women than among men
At least twice as many men than women suffer from 
drug use disorders. However, once women have ini-
tiated substance use, in particular, use of alcohol, 
cannabis, opioids and cocaine, they tend to increase 
their rate of consumption more rapidly than men. 
As a result, women may progress more rapidly than 
men to drug use disorders. Women’s access to treat-
ment for drug use disorders is also more limited 
than men’s.
In the past decade, the negative health impact of 
drug use has increased more rapidly among women 
than among men. The rate of increase in the number 
of DALYs attributed to drug use disorders in 2015, 
particularly opioid and cocaine use disorders, was 
greater among women (25 per cent and 40 per cent, 
respectively) than among men (17 per cent and 26 
per cent, respectively). 
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20% 5.3%
+25% +19%
Higher rate of increase in the burden 
of disease from drug use disorders
among women than among men
2005 2015 2005 2015
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Interregional trafficking flows of “ecstasy”, 2012-2015
Source: UNODC elaboration, based on responses to annual report questionnaire, 2012-2015.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of "ecstasy". Flow arrows represent the direction of "ecstasy" 
trafficking and are not an indication of the quantity trafficked. The boundaries shown on this map do not imply official endorsement or acceptance by 
the United Nations. Dashed lines represent undetermined boundaries. The dotted line represents approximately the Line of Control in Jammu and 
Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary 
between the Sudan and South Sudan has not yet been determined.
medical practice, are posing serious public health 
concerns. In particular, the use of a combination of 
different opioids and other psychoactive substances 
is causing many opioid-related deaths.
New psychoactive substances continue to 
evolve, diversify and grow 
The NPS market continues to be very dynamic and 
is characterized by the emergence of large numbers 
of new substances belonging to diverse chemical 
groups. Between 2009 and 2016, 106 countries and 
territories reported the emergence of 739 different 
NPS to the United Nations Office on Drugs and 
Crime (UNODC). 
Marketed in many different ways and forms, new 
substances often emerge quickly and disappear 
again, while some become used regularly among a 
small group of users. Several countries have reported 
NPS being sold under the name of controlled drugs 
such as “LSD” and “ecstasy”. Often used for reasons 
similar to those for the use of traditional drugs, their 
easy availability and low prices have made certain 
Range of 
new psychoactive substances 
 continues to grow
reported in 
2012
reported in 
2015
26
0  N
PS 48
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Source: UNODC, responses to annual report questionnaire, 2012-2015.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of ecstasy. Flow arrows represent the direction of ecstasy trafficking and are not an indication of the quantity trafficked. 
The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined boundaries. The dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir 
has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).
Significant flows within region
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natural cannabis, the use of products containing 
certain synthetic cannabinoids has been associated 
with severe adverse health events including hospi-
talisations and fatalities. It cannot be concluded, 
however, that the untoward or undesirable effects of 
synthetic cannabinoids will limit their uptake or use.
The drug market is thriving
Overall, drug trafficking seems to have increased 
slightly in 2015 and some drug markets, particularly 
the cocaine and synthetic drugs markets, appear to 
be thriving. 
Expansion of the cocaine market
Data on drug production, trafficking and use point 
to an overall expansion of the market for cocaine 
worldwide. Following a long-term decline, coca bush 
cultivation increased by 30 per cent during the 
period 2013-2015, mainly as a result of increased 
cultivation in Colombia. Total global manufacture 
of pure cocaine hydrochloride reached 1,125 tons 
in 2015, representing an overall increase of 25 per 
cent over 2013.
Cocaine use appears to be increasing in the two 
largest markets, North America and Europe. The 
prevalence of use of cocaine among the general pop-
ulation and testing in the workforce suggest an 
NPS highly attractive to some groups of drug users. 
A market for some NPS in their own right now 
appears to have been established.
A core group of over 80 NPS were reported every 
year during the period 2009-2015 and appear to 
have become established on the global market; a 
number of them have been placed under interna-
tional control. On the other hand, about 60 NPS 
seem to have disappeared from the market since 
2013. Problems in identifying them in a laboratory 
may be a factor, however, in the low level of report-
ing of these lesser-known substances. 
“Ecstasy” market becoming increasingly 
multifaceted
While smaller than the market for methampheta-
mine, the “ecstasy” market has grown in complexity 
and the variety of “ecstasy” products available to 
drug users has increased. The three main types are: 
(a) “ecstasy” tablets containing little or no MDMA 
(3,4-methylenedioxymethamphetamine); (b) 
“ecstasy” tablets with an extremely high content of 
MDMA; and (c) “ecstasy” sold in powder or crystal 
form, under different street names. “Ecstasy” tablets 
with a high MDMA content are of particular con-
cern in Europe, where law enforcement entities have 
also discovered industrial-scale MDMA manufac-
turing facilities. 
Crossover between plant-based and  
synthetic cannabinoids
Synthetic cannabinoids are not simply synthetic 
versions of the substances occurring in herbal can-
nabis, as street names such as “synthetic cannabis” 
or “synthetic marijuana” may suggest. They are a 
diverse group of potent psychoactive compounds 
that are a substitute for natural cannabis, of which 
there are also many new products on the market. 
Despite the predominance of synthetic cannabinoids 
on the spectrum of NPS, users of cannabis have 
reported that they prefer natural cannabis. They 
perceive the use of synthetic cannabinoids to be 
associated with more overall negative effects than 
the use of natural cannabis.
There is growing recognition of the harm associated 
with intoxication resulting from the use of synthetic 
cannabinoids. While, in general, these health harms 
are not dissimilar to the intoxication caused by 
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* 57 tons of which 34 tons represent seizures of GBL, ketamine 
and other medicines, see booklet 4.
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increase in cocaine use in the United States. In 
Europe, early signs of increases in cocaine consump-
tion, based on wastewater analysis in selected cities, 
have been reported, with an increase of 30 per cent 
or more during the period 2011-2016. 
The quantities of cocaine seized are also on the 
increase. Worldwide, they increased by 30 per cent 
to reach 864 tons (of varying purities) in 2015, the 
highest level ever reported. In North America, they 
increased by 40 per cent to reach 141 tons; in Europe, 
they increased by 35 per cent to reach 84 tons.
Opium production on the increase 
In 2016, global opium production increased by one 
third compared with the previous year. Although 
there was also an increase in the size of the area under 
opium poppy cultivation, the major increase in 
opium production was primarily the result of an 
improvement in opium poppy yields in Afghanistan 
compared with the previous year. At 6,380 tons, 
however, total global opium production was still 
some 20 per cent lower than at its peak in 2014, 
and was close to the average reported in the past five 
years. 
Seizures of both opium and heroin have remained 
quite stable at the global level in recent years, sug-
gesting a smooth supply of heroin, irrespective of 
annual changes in opium production. The quantity 
of heroin seized in North America increased sharply 
in 2015. This went in parallel with reports of 
increasing heroin use and heroin-related deaths in 
that subregion. 
Expanding market for synthetic drugs 
Unlike the manufacture of heroin and cocaine, the 
manufacture of synthetic drugs is not geographically 
constrained, as the process does not involve the 
extraction of active constituents from plants that 
have to be cultivated in certain conditions for them 
to grow. Yet any analysis of the synthetic drugs 
market is complicated by the fact that information 
on synthetic drug manufacture is limited, which 
prevents the estimation of the volume of such drugs 
being manufactured worldwide. Nevertheless, data 
on seizures and use suggest that the supply of syn-
thetic drugs is expanding.
An increasing number of countries are reporting 
seizures of synthetic NPS, with over 20 tons seized 
opiates
Number of  countr ies report ing  drug se izures,  
based on 168 countries ,  2010-2015
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Main cocaine trafficking flows, 2011-2015
Source: UNODC elaboration, based on responses to annual report questionnaire and individual drug seizure database.
Notes: The trafficking flows are determined on the basis of country of origin/departure, transit and destination of seized drugs as reported by Member 
States in the annual report questionnaire and individual drug seizure database: as such, they are to be considered as broadly indicative of existing  
trafficking routes while several secondary flows may not be reflected. Flow arrows represent the direction of trafficking: origins of the arrows indicate 
either the area of manufacture or the one of last provenance, end points of arrows indicate either the area of consumption or the one of next  
destination of trafficking. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines rep-
resent undetermined boundaries. The dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Paki-
stan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan 
has not yet been determined. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland 
concerning sovereignty over the Falkland Islands (Malvinas).
share of people treated for drug use in the majority 
of countries and territories in East and South-East 
Asia that reported on that indicator. 
In Oceania, there has been an increase in both the 
quantities of methamphetamine seized and the prev-
alence of its use.
Increasingly effective law enforcement 
Reflecting improvements in international coopera-
tion, law enforcement appears to be becoming 
increasingly effective. Evidence of this is the fact 
that the estimated global interception rate of cocaine 
increased to between 45 and 55 per cent in 2015, 
a record level. The estimated global interception 
rate of opiates also rose from between 9 and 13 per 
cent during the period 1980-1997 to between 23 
and 32 per cent during the period 2009-2015. 
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Main trafficking 
Other trafficking 
Most frequently mentioned countries of provenance as 
reported by countries where cocaine seizures took place
in 2015. Seizures of amphetamine-type stimulants 
(ATS) doubled in the five years prior to 2015, to 
reach 191 tons in 2015. This was a result of sharp 
increases in the amounts of amphetamines seized, 
of which methamphetamine accounted for some 
61-80 per cent annually during that period. 
The expansion of the methamphetamine market in 
East and South-East Asia is visible in the, albeit 
scarce, information available on methamphetamine 
use and treatment for such use. In 2015, experts in 
several countries in the subregion reported a per-
ceived increase in the use of both crystalline 
methamphetamine and methamphetamine tablets. 
They also considered methamphetamine to be the 
most commonly used drug in some of those coun-
tries. In the same year, people receiving treatment 
for methamphetamine use accounted for the largest 
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Main opiate trafficking flows, 2011-2015
Sources: UNODC elaboration, based on responses to annual report questionnaire and individual drug seizure database.
Notes: The trafficking flows are determined on the basis of country of origin/departure, transit and destination of seized drugs as reported by Member 
States in the annual report questionnaire and individual drug seizure database: as such, they are to be considered as broadly indicative of existing  
trafficking routes while several secondary flows may not be reflected. Flow arrows represent the direction of trafficking: origins of the arrows indicate 
either the area of manufacture or the one of last provenance, end points of arrows indicate either the area of consumption or the one of next  
destination of trafficking. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines 
represent undetermined boundaries. The dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and 
Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South 
Sudan has not yet been determined. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern 
Ireland concerning sovereignty over the Falkland Islands (Malvinas).
That route circumvents Turkey, where the recent 
increase in flows of refugees heading towards 
countries in the European Union may have pushed 
traffickers to seek other options. 
Data show that quantities of heroin and morphine 
seized declined in Bulgaria, Greece and Turkey 
during the period 2014-2015 compared with the 
period 2012-2013. By contrast, the amounts inter-
cepted on the trafficking route through Armenia, 
Azerbaijan and Georgia, and via the Black Sea to 
Ukraine and Romania, increased sharply between 
those two periods. 
Geographical shift in the  
methamphetamine market
A major geographical shift appears to have occurred 
in the methamphetamine market in the last five 
years. In 2015, the quantity of methamphetamine 
Flux in drug flows
Drug flows are in a constant state of flux. With the 
changes brought by globalization and the spread of 
new communication technologies, drug flows are 
characterized more than ever by rapid changes in 
trafficking routes, modi operandi and concealment 
methods.
Growing importance of Caucasus branch 
of the Balkan route 
With about 40 per cent of global heroin and 
morphine seizures in 2015 being made in countries 
on the so-called “Balkan route”, the route appears 
to remain the world’s principal opiate trafficking 
route. While overall quantities seized on the Balkan 
route declined in 2015, an alternative branch of the 
route, through the Caucasus countries, appears to 
have been gaining in importance in recent years. 
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Interregional trafficking flows of methamphetamine, 2012-2015
Source: UNODC, responses to annual report questionnaire, 2012-2015.
Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of methamphetamine. Flow arrows represent the 
direction of methamphetamine trafficking and are not an indication of the quantity trafficked. The boundaries shown on this map do not 
imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined boundaries. The dotted line represents 
approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not 
yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
the neighbouring Near and Middle East. Quantities 
of amphetamine seized also sharply increased in 
Central America and South-West Asia.
Cocaine trafficking expanding eastwards 
Although still comparatively small overall, there are 
indications that cocaine markets in several countries 
in Asia continue to rise. Possible proof of this was 
a very large seizure (900 kg) of cocaine in Sri Lanka 
in 2016 and another of 500 kg in Djibouti in 2017, 
which was probably en route to Asia. That was the 
single largest cocaine seizure in East Africa since 
2004. 
Overall, in 2015, the quantities of cocaine inter-
cepted in Asia increased by more than 40 per cent 
compared with the previous year, with increases 
reported across all subregions. The largest propor-
tions of the total quantity of cocaine seized in Asia 
over the period 2010-2015 were seized in East and 
South-East Asia (56 per cent) and in the Near and 
Middle East (40 per cent). 
intercepted in East and South-East Asia surpassed 
the quantity intercepted in North America for the 
first time, making East and South-East Asia the lead-
ing subregions for methamphetamine seizures 
worldwide. While this may be a reflection of an 
increase in the effectiveness of law enforcement in 
East and South-East Asia, methamphetamine traf-
ficking routes appear to be increasingly connecting 
previously unconnected markets in various subre-
gions. Of particular note is the large increase in 
methamphetamine seizures in China.
Amphetamine trafficking expanding in 
Asia and Central America
In contrast to methamphetamine, amphetamine has 
been confined to fewer subregions, such as the Near 
and Middle East and Western and Central Europe. 
The quantities of amphetamine seized in 2015 point 
to a possible recent expansion of the amphetamine 
market in South-Eastern Europe, but this may be 
simply related to the large amphetamine market in 
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Jurisdictions in the United States that allow recreational use, medical use of cannabis and those 
that allow no access to cannabis
Source: Based on information from the National Conference of State Legislatures (NCSL) as of 12 May 2017.
Notes: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations.
Cannabis market developments 
Most jurisdictions in the United States 
now permit access to medical cannabis 
while nine allow the cultivation of  
cannabis for recreational use 
The latest voter initiatives in the United States, in 
2016, allowed the legalization of cannabis for rec-
reational use in an additional four states. Recreational 
use of cannabis is now permitted in eight states and 
the District of Columbia. Of greater importance is 
that in those jurisdictions, with the exception of the 
District of Columbia, licences are now granted to 
for-profit companies to produce and sell a range of 
products for the medical and non-medical use of 
cannabis. 
In the jurisdictions where the recreational use of 
cannabis is now permitted, cannabis use has 
increased among the adult population and remains 
higher than the national average. This trend pre-
ceded the change in legislation in those jurisdictions, 
however. It is difficult to quantify the impact of the 
new cannabis legislation as it seems that a combina-
tion of elements was already in the process of 
changing the cannabis use market in those jurisdic-
tions when the legalization measures were put in 
place. 
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trafficking, while more are also operating in other 
illicit sectors.
Almost two thirds of drug trafficking groups oper-
ating in countries in the European Union are 
involved in more than one crime area, according to 
research by the European Police Office (Europol), 
and that figure has been rising for years. Drug traf-
ficking groups in Europe are frequently also involved 
in the counterfeiting of goods, trafficking in human 
beings, smuggling of migrants and trafficking in 
weapons. 
Continued importance of drugs to  
organized crime groups
In 2014, transnational organized crime groups across 
the globe were estimated to have generated between 
approximately one fifth and one third of their rev-
enues from drug sales. 
Europol identified some 5,000 international organ-
ized crime groups operating in countries in the 
European Union in 2017, and estimated that more 
than one third were involved in drug trafficking. 
This makes drug trafficking more widespread across 
organized crime than organized property crime, 
smuggling of migrants, trafficking in human beings, 
excise fraud or any other illicit activity.
Drug trafficking no longer the preserve  
of large criminal groups
Groups with a strong hierarchical structure, such as 
those in Mexico and Japan, and to some extent in 
the Russian Federation, continue to be involved in 
the drug trade. Hierarchical, top-down organizations 
are still the most widespread type of organized crime 
group in Europe, according to Europol.
The major increase in cannabis use in those juris-
dictions started in 2008, in parallel with measures 
allowing the medical use of cannabis (although the 
cannabis products dispensed have not gone through 
the rigours of pharmaceutical product development), 
decreasing risk perceptions of harm from cannabis 
use and an ongoing debate around the legalization 
of the medical and recreational use of cannabis. 
Since the approval of legalization measures, the 
increasing trend in cannabis use in those jurisdic-
tions has continued. 
Yet while the increases in those jurisdictions are more 
marked than in states where such use has not been 
legalized, cannabis use has increased at the national 
level. The developments observed in the jurisdictions 
where the use of cannabis has been legalized 
(including the perception of risk of harm from 
cannabis use) appear to have affected the cannabis 
market and users’ perceptions of cannabis nationwide. 
It has been observed that increases in cannabis use 
across the United States are disproportionally 
associated with adults with a low socioeconomic 
status who are regular and heavy users of cannabis. 
Cannabis regulation in Uruguay
In 2013, the Government of Uruguay approved 
legislation regulating the cultivation, production, 
dispensing and use of cannabis for recreational 
purposes. Since then, the Government has passed 
additional decrees and ordinances concerning the 
implementation of specific elements of the cannabis 
regulations. They include regulating the medical use 
of cannabis, the marketing and dispensation of 
cannabis for recreational use, including through 
pharmacies, and the registration of recreational 
cannabis users. However, the impact of the provisions 
regulating the recreational use of cannabis in 
Uruguay will be evident only after they have been 
fully implemented, and will require close monitoring 
over time.
Changing business models for drug 
trafficking and organized crime
Organized crime groups branch out
Organized crime groups have widened their port-
folio of illicit activities. New crime areas such as 
cybercrime and environmental crime have emerged. 
Fewer groups are exclusively dedicated to drug 
smuggling
of migrants
over 35 per cent of
all organized crime 
groups involved
excise 
fraud
drug trafficking
trafficking
in human
beings
organized
property
crime
Importance of organized crime groups, European Union
Source: UNODC, adapted from Europol, SOCTA 2017.
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delivered to them in a concealed manner. Typical 
buyers are recreational users of cannabis, “ecstasy”, 
cocaine, hallucinogens and NPS. They are less likely 
to order heroin or methamphetamine. Although the 
darknet accounts for only a small percentage of drug 
sales, the market has been growing rapidly in recent 
years.
Drug crime proceeds damage  
economies in the long term
About 30 per cent of cocaine proceeds 
contributes to illicit financial flows
About 30 per cent of the proceeds of cocaine sales 
at the global level was laundered abroad in 2009, 
according to a model developed by UNODC. A 
2016 study based on interviews with drug crime 
convicts in Italy came to a similar conclusion, 
suggesting that roughly one third of the money spent 
by cocaine users was being laundered across borders.
Drug money can make countries poorer
In the short term, an inflow of drug money can 
boost investment and local gross domestic product. 
But the long-term effects tend to be negative, 
particularly when drug-related proceeds comprise a 
sizeable portion of the total economy of a community 
or a country. In this scenario, drug money has the 
potential to inflate property prices, distort export 
figures, create unfair competition, reinforce skewed 
income and wealth distributions and increase 
corruption. In the process, legitimate businesses, 
without access to illicit funds, may be squeezed out 
of the market and new legitimate investments may 
not take place. 
The rise of an illicit economy helps to weaken the 
rule of law and facilitates corruption, which in turn 
reinforces the illicit drug sector. 
Studies suggest that an injection of laundered 
money, including from illicit drug activities, is asso-
ciated with reductions in overall annual economic 
growth rates, particularly in smaller and less devel-
oped countries. One estimate, based on a study of 
However, there is evidence that looser, horizontal 
networks are becoming increasingly significant. In 
2017, Europol estimated that such networks 
accounted for 30-40 per cent of organized crime 
groups operating in countries in the European 
Union.
Technology’s role in creating relatively 
low-risk drug markets
The mobile communications revolution has offered 
new opportunities to traffickers. They no longer 
need personal contact with clients; instead, low-level 
“runners” can collect cash and dealers can let the 
customer know where to collect their drugs using 
messages sent over encrypted networks.
The darknet allows users to buy drugs with a cryp-
tocurrency, such as bitcoin, and have their purchases 
DRUG PROCEEDS
illicit nancial ows
related to drugs
domestic international =
Gross profit of drugs = drug proceeds − cost of drugs
Profits available for laundering =
Net profit of drugs = gross profit − trafficking costs*
* Transportation costs, intermediaries, bribes, etc.
** Living expenses, luxury goods, cars, etc.
  net profit − living expenses of traffickers** 
DARKNET
drug
transactions
drug
transactions
DARKNET
Drug trafficking over the darknet
still small but fast growing
<1%
+50%
increase
201
5
201
3
per year
Kristy Kruithof and others, Internet-facilitated Drugs Trade: An 
Analysis of the Size, Scope and the Role of the Netherlands, 
Research Report Series (Santa Monica, California, Rand Corpo-
ration, 2016).
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Afghanistan. Further, the Consolidated United 
Nations Security Council Sanctions List contains a 
number of Taliban leaders who are accused of direct 
involvement in drug trafficking.
UNODC estimated that non-State armed groups 
raised about $150 million in 2016 from the Afghan 
illicit opiate trade in the form of taxes on the culti-
vation of opium poppy and trafficking in opiates. 
The overall drug-related income, however, may be 
higher still. The Security Council Committee estab-
lished pursuant to resolution 1988 (2011) estimated 
the overall annual income of the Taliban at about 
$400 million, half of which is likely to be derived 
from the illicit narcotics economy.
Role of the Revolutionary Armed Forces of 
Colombia in the drug trade
The involvement of the Revolutionary Armed Forces 
of Colombia (FARC) in the drug trade in Colombia 
goes back decades. At various times, they have pro-
vided security for coca crops, taxed the introduction 
of precursor chemicals and the use of landing strips, 
sold coca paste and become involved in the intrare-
gional cocaine trade. 
FARC agreed in 2016 to halt its involvement in the 
drug business after the peace agreement signed with 
the Government.
Evidence implicating other groups is thin 
Media reports and some evidence from official 
sources link a number of other terrorist, insurgent 
and non-State armed groups to the drug trade. For 
example, media reports claim that Islamic State in 
Iraq and the Levant (ISIL) and other armed groups 
in Iraq and the Syrian Arab Republic produce and 
consume “captagon” tablets — typically ampheta-
mine mixed with caffeine. The group operates in an 
area likely to be a manufacturing hub, according to 
seizure data, but no conclusive evidence has emerged 
so far, as other groups also operate in the same area.
Boko Haram has also reportedly helped drug traf-
fickers to smuggle heroin and cocaine across West 
Africa. During the trial of Boko Haram members 
in Chad, the court of appeal heard that considerable 
quantities of psychotropic substances had been 
recovered and that Boko Haram members were regu-
larly involved in the trafficking in and consumption 
17 countries of the Organization for Economic 
Cooperation and Development, suggests that a $1 
billion increase in money-laundering could reduce 
overall economic growth by between 0.03 and 0.06 
percentage points.
Corruption facilitates illicit drug  
markets, which fuel corruption
Corruption exists all along the drug supply 
chain
At each stage of the drug supply chain, there are 
opportunities for corruption. At the production 
level, farmers may bribe eradication teams, producers 
may bribe judges and police officers, and 
manufacturers may exploit workers in chemical 
companies in order to get hold of precursor 
chemicals. Further down the chain, traffickers bribe 
customs officials and take advantage of weaknesses 
in transport firms. At the consumer level, users can 
get drugs through corrupt doctors and pharmacists.
Corruption, the illicit drug trade and  
poverty reinforce each other
Corruption entrenches poverty by discouraging 
foreign investment, according to World Bank 
research. In a narco-economy, this is doubly true. 
Foreign firms, seeing the corrupted justice system 
and pervasive money-laundering that characterize 
narco-economies, are unlikely to make or increase 
investments.
Corruption also increases the level of income 
inequality, according to International Monetary 
Fund research. Higher levels of income inequality 
are known to encourage drug trafficking and 
corruption. In fact, the drug industry may perpetuate 
and exacerbate income inequality, which may in 
turn cause the expansion of drug production and 
trafficking.
Drug trade benefiting some terrorist, 
insurgent and non-State armed 
groups 
United Nations-designated terrorist 
groups: Taliban continues to benefit
The Taliban’s involvement in the drug trade is well 
documented. It has taxed entities involved in illicit 
opiate production, manufacture and trafficking in 
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Income from drugs key for some terrorist, 
insurgent and non-State armed groups
Much depends on the location of a particular group. 
Some have benefited from being based in areas 
where drug crops flourish. Groups that aspire to 
control large amounts of territory need huge finan-
cial resources, and have relied on organized crime 
and the illicit drug trade to fund their ambitions. 
of those substances. Further north, some evidence 
suggests that Al-Qaida in the Islamic Maghreb has 
been involved in cannabis and cocaine trafficking, 
or at least in protecting traffickers, but that its over-
all income from the drug sector appears to have been 
rather modest.
Sectors vulnerable to corruption in relation to drugs
Source: EUROSTAT.
DRUG PRODUCTION
DRUG CONSUMPTION
DRUG TRAFFICKING
• Eradication teams
• Alternative  development
projects
• Law enforcement 
(police, customs, etc.)
• Criminal justice system
• Chemical companies
• Traffickers seek to avoid 
controls, dismantlement of 
groups and arrest
• Drug users seek to obtain 
prescriptions for non-medical use 
of drugs (e.g., opioids, ampheta-
mines, medical cannabis)
• Law enforcement 
(police, customs, etc.)
• Criminal justice system
• Transport companies
• Farmers seek to avoid eradication 
on their fields
• Farmers and communities seek 
to benefit from alternative 
development investment
• Entrepreneurs seek to sell their 
products and services
• Producers and manufacturers seek 
to avoid controls, dismantlement 
of production sites and arrest
• Producers and manufacturers 
seek to avoid sentencing
• Manufacturers seek to divert 
precursor chemicals
 
• Traffickers seek to ship drugs 
by air, sea, land
• Drug users seek to obtain 
medicines without prescription
• Traffickers seek to avoid 
sentencing
• Medical doctors
• Pharmacies
ActorsVulnerable sectors
Supply
chain
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of corruption. While these approaches have certain 
strengths, they highlight a paucity of data on the 
links between drugs and corruption across countries. 
For example, while, intuitively, such a correlation 
is anticipated, in terms of research, little is known 
about the way that different types of corruption 
interact with drug markets and political structures; 
the way that corruption and violence coexist also 
needs further investigation. 
Huge variation in estimates of finances  
of terrorist, insurgent and other non-State 
armed groups 
Little reliable data exist for estimating the overall 
wealth of terrorist, insurgent and other non-State 
armed groups, making it tricky to estimate the 
importance of the drug trade. Forbes International 
attempted to compile a list, but the income of the 
Just one revenue stream of many  
for most groups
Terrorist and other non-State armed groups are 
adept at tapping into multiple sources of revenue. 
If drug profits dry up, the groups may move into 
extortion, kidnapping for ransom, bank robberies, 
sale of natural resources or sale of cultural artefacts. 
However, groups aiming simply to stage shocking 
attacks on civilians can do so with negligible finan-
cial investment.
Scarcity of reliable data on terrorism 
and corruption 
Lack of understanding of the relationship 
between drugs and corruption 
Many studies have focused on specific events or 
geographical areas; others have relied on perceptions 
Area under control of insurgent groups and area under opium poppy cultivation in  
Afghanistan, 2016
Source: MCN and UNODC, Afghanistan Opium Survey 2016 – Cultivation and Production (Vienna, 2016). Insurgency groups 
taken from the Institute for the Study of War, November 2016.
Note: the boundaries and names shown and the designations used on this map do not imply official endorsment or acceptance by the 
United Nations. Dashed lines represents undetermined boudaries. Dotted line represents approximately the Line of Control in Jammu and 
Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. 
The insurgency groups are mapped with different classes of confidence, which have been merged for the purpose of this map.Geographic 
projection: WGS 84.
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wealthiest 10 groups (around $5 billion together) 
was highly skewed, ranging from $25 million to $2 
billion per group.
Limited evidence on drugs, terrorism  
and insurgency 
Much of the work in this area tracks a small number 
of groups, or builds on sources with an interest in 
emphasizing or diminishing certain links. Most 
information on terrorism is collected by intelligence 
agencies and is classified, meaning that researchers 
have to rely on media reports and studies issued by 
non-governmental organizations and think tanks.
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As opioids continue to cause the 
highest negative health impact 
related to drug use, preventing 
and treating opioid use remain 
 a priority 
Seventy per cent of the global burden of disease 
caused by drug use disorders is attributable to opioid 
use. The following interventions remain key to the 
reduction of that burden: preventing drug use in 
families, schools and communities using sci-
ence-based methods that are effective in addressing 
individual and environmental vulnerabilities; treat-
ment and care of opioid use disorders; and 
prevention of their negative health consequences. 
In most countries with high levels of opioid use, 
this would include scaling up prevention of opioid 
overdose through community access to naloxone 
and long-term medication-assisted psychosocial 
treatment and care for opioid use disorders (com-
prising interventions such as cognitive behavioural 
therapy and contingency management). 
GOOD HEALTH
AND WELL-BEING
Scaling up prevention and 
treatment of drug use disor-
ders to meet target 3.5 of the 
Sustainable Development 
Goals by 2030...
Two years on from the adoption of target 3.5 of the 
Sustainable Development Goals, on strengthening 
the prevention and treatment of substance abuse, 
there is still no sign of improvement in the provision 
of drug treatment services — as few as one in six 
people in need of interventions have access to drug 
treatment. The availability and access to scientific 
evidence-based intervention for treatment of drug 
use disorders remains limited in many countries. 
Global standards developed by UNODC and the 
World Health Organization (WHO) on the treat-
ment of drug use disorders need to be better integrated 
within health-care systems across all countries to 
ensure that the policies and interventions available 
are effective and based on scientific evidence.
In an environment where risk perceptions and social 
norms affect attitudes and behaviour towards the 
use of drugs such as cannabis, effective prevention 
strategies and interventions are needed more than 
ever. The UNODC International Standards on Drug 
Use Prevention provide scientific evidence for the 
interventions and policies that have been found to 
be effective and result in positive prevention out-
comes. In the context of use of cannabis and other 
drugs by adults, interventions such as screening and 
brief interventions (SBI) address the harmful pat-
terns of adult substance use and prevent progression 
to disorders. 
REDUCED
INEQUALITIES
…leaving no one behind
First and foremost, no one should be 
left behind in the delivery of preven-
tion and treatment interventions. 
Interventions and services should be tailored to the 
specific needs of different population subgroups. 
Drug use by women, men who have sex with men 
and by many marginalized groups, including sex 
workers, often leads to them suffering a double stig-
matization. Such groups require dedicated 
prevention and treatment services. In this context, 
it is worrying that some NPS have found a niche 
among vulnerable population groups such as the 
homeless, who are often not well covered by health 
services. 
People who use drugs are overrepresented in prison 
populations in many countries, so it is also import-
ant to mainstream science-based drug prevention 
and treatment efforts and HIV prevention, treat-
ment and care into national prison systems. The 
standard of care provided to those who are incar-
cerated should be equivalent to that received by 
those outside prison, with appropriate continuity 
of care between prison and the wider community 
(in line with the United Nations Standard Minimum 
Rules for the Treatment of Prisoners (the Nelson 
Mandela Rules)). 
CONCLUSIONS AND POLICY IMPLICATIONS  
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Access to effective treatment for 
hepatitis C key to reducing the very 
heavy burden of disease among 
people who use drugs 
Hepatitis C has a substantially greater negative 
health impact on people who use drugs than HIV, 
and results in far more deaths and years of “healthy” 
life lost as a result of premature death and disability. 
Recent advances in the development of direct-acting 
antivirals have brought in a new era for the treat-
ment of hepatitis C, but their high cost prevents 
many people from benefiting from them. To prevent 
hepatitis C infection and reinfection after treatment 
for those injecting opioids, access needs to be 
expanded to hepatitis C prevention and treatment. 
This includes affordable access to direct-acting anti-
virals, increased awareness and increased access to 
diagnosis, needle and syringe programmes, also fea-
turing low dead-space syringes, and long term opioid 
agonist treatment. The role of the community in 
prevention and treatment response is a key factor 
in its effectiveness. 
Addressing the specific  
challenges and needs of people 
who use drugs and suffer from 
drug use disorders is integral to 
ending tuberculosis
People who use drugs are at a greater risk of becom-
ing infected with tuberculosis than those who do 
not, and people who inject drugs (PWID) and/or 
are living with HIV are disproportionately affected. 
They should therefore be considered a priority group 
for the prevention, diagnosis and treatment of tuber-
culosis. There is a need to engage people who use 
drugs with prevention and treatment services in 
order to cure tuberculosis, prevent the development 
of drug-resistant forms of the disease and prevent it 
spreading.
For people who use drugs, treatment for tuberculosis 
needs to be combined with prevention and treat-
ment services for other infectious diseases, 
particularly HIV, as well as for drug dependence as 
a continuum of care within the health-care system.
The co-location of services for tuberculosis with 
HIV services, needle and syringe programmes and 
drug treatment, including opioid substitution ther-
apy, alongside a multidisciplinary approach to care 
and management and closer collaboration between 
health, social welfare and prison authorities, could 
improve adherence to treatment and enhance health 
outcomes.
Improvement of coverage of  
evidence-based prevention and 
treatment services is needed to stop 
the rising number of new HIV cases 
among people who inject drugs and to 
meet target 3 of the Sustainable Develop-
ment Goals 
The target of reducing by 50 per cent HIV trans-
mission among PWID by 2015, set in the 2011 
Political Declaration on HIV and AIDS: Intensify-
ing Our Efforts to Eliminate HIV and AIDS, has 
not been met. New HIV infections among PWID 
climbed from 114,000 in 2011 to 152,000 in 2015; 
an increase of 33 per cent.
Renewed impetus is needed to achieve target 3.3 of 
the Sustainable Development Goals (ending the 
AIDS epidemic by 2030). Removing barriers and 
increasing access to and coverage of evidence-based 
prevention and treatment services, such as those 
recommended in the WHO, UNODC, UNAIDS 
Technical Guide for Countries to Set Targets for Uni-
versal Access to HIV Prevention, Treatment and Care 
for Injecting Drug Users,1 would help reduce the 
number of new cases of HIV among PWID. 
Alternatives to incarceration 
for possession, purchase,  
or cultivation for personal 
consumption and appropriate 
cases of a minor nature: an 
effective human rights-based criminal  
justice response and an effective policy  
for preventing the spread of  infectious 
diseases
People who use drugs may have a history of greater 
exposure to the risk factors for infectious diseases 
than people in the general population. In prison, 
people who use drugs are exposed to a high-risk 
environment for infectious diseases such as HIV, 
hepatitis C and tuberculosis. The use of drugs, 
including heroin, and unsafe injecting practices con-
tinue in many prisons. These factors contribute to 
the overall high prevalence and co-infection of 
1  Geneva, WHO, 2009.
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infectious diseases observed in many prison popula-
tions. Alternatives to incarceration for offences of a 
minor nature help reduce the spread and burden of 
infectious diseases in prisons, and ultimately within 
the wider community. The international drug con-
trol conventions give States parties the flexibility to 
adopt such an approach through referral from the 
criminal justice system to the treatment system.  
Continuous monitoring of  
the impact of new cannabis 
policies provides an important 
knowledge base for the  
international community 
It will take years to determine the long-term impact 
of regulations approved in Uruguay and in some 
jurisdictions in the United States of America allow-
ing the production and sale of cannabis for 
recreational use. However, the regular monitoring 
of the public health and safety, criminal justice and 
other outcomes of those regulations will continue 
to provide valuable insights. It would be beneficial 
to the countries concerned, and to the international 
community in general, if jurisdictions and countries 
adopting new regulations were to establish systems 
to regularly monitor their impact across all areas of 
public health and criminal justice. 
Medical use of cannabis needs 
a scientific approach 
Research has shown that, notwith-
standing the usefulness of some 
cannabinoids in the management of specific medical 
conditions, their use, particularly in the botanical 
form of herbal cannabis with unknown content and 
dosage, can be detrimental to health. To protect 
human health, it is therefore necessary that the prin-
ciples of safety, quality and efficacy and the rigorous 
scientific testing and regulatory systems that apply 
to established medicines be applied also to cannabis-
based medicines. 
Improving access to and  
availability of pharmaceutical 
opioids for medical use by 
addressing major impediments 
and putting in place adequate legal and 
regulatory frameworks
Too many people lack access to pain medication. 
The implementation of the international drug 
control conventions need not be an obstacle to the 
availability of such medication, as their aim is to 
ensure the availability of controlled substances for 
medical and scientific purposes while preventing 
their diversion and misuse. Legal and regulatory 
frameworks and clinical guidelines based on that 
balanced approach can help remove any obstacles 
and increase accessibility to pharmaceutical opioids 
while reducing the risk of their diversion. The vari-
ous guidelines and discussion papers prepared by 
UNODC, INCB and WHO can be used as a 
resource for addressing these issues.
Benefit of regional and interna-
tional cooperation and its role in 
the fight against drug trafficking 
The increased interception rates observed 
for opiates and cocaine since the 1990s demonstrate 
that when countries engage in regional, interregional 
and international cooperation they achieve results. 
It is encouraging to see the international community 
maintaining its commitment to cross-border coop-
eration at the core of its efforts to address the drug 
problem, as reiterated in the outcome document of 
the special session of the General Assembly on the 
world drug problem held in 2016. 
While interception rates are not available for syn-
thetic drugs, the expanding market and trafficking 
routes for methamphetamine, in particular, require 
increased international cooperation in order to sup-
port countries with a limited capacity to detect and 
address the methamphetamine problem.
Complexity of the synthetic drugs 
market requires enhanced forensic 
capacity 
The synthetic drugs market has never been 
so complex and widely spread. In partic-
ular, the range of substances on the market with 
stimulant effects, such as traditional amphetamine 
type-stimulants and NPS, is increasing. The rapid 
evolution of synthetic drugs requires forensic capac-
ity with adequate equipment and human resources, 
together with new approaches to collecting data on 
drug use, as many users are often ignorant about 
the compound they are taking. 
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Better understanding of the 
harm to health caused by new 
psychoactive substances 
requires a global information 
system on pharmacology and 
toxicology 
NPS are proliferating at an unprecedented rate and 
have been reported by over 100 countries and ter-
ritories worldwide, but understanding what 
substances or subpopulation groups to prioritize 
when addressing the problem requires a global infor-
mation system capable of assessing the health 
consequences of each substance. This necessitates 
the collection of more information on the pharma-
cology and toxicology of these substances and the 
management of their acute and chronic adverse 
effects. Early warning systems, risk communication 
strategies and the development of guidelines for the 
management of NPS-related adverse effects can con-
tribute significantly to efforts to protect human 
health and welfare. In the meantime, health workers 
in emergency settings can and should be trained in 
the clinical management of incidents caused by those 
effects. 
Long-term and large-scale  
sustainable development  
interventions twinned with 
drug control strategies can 
reverse recent increases in opium poppy 
and coca bush cultivation
Promoting sustainable development, with its fun-
damental elements of social, economic and 
environmental development, together with peace, 
justice and transparent institutions, remains the best 
response to helping farmers to abandon illicit drug 
cultivation. Only the strengthening of the rule of 
law, lasting peace and the provision of alternative 
sources of income can break the vicious circle of 
poverty, lack of security and illicit crop cultivation. 
The drivers of illicit drug cultivation are multifac-
eted and vary across and within countries. Research 
therefore continues to be instrumental in the under-
standing of the factors contributing to illicit crop 
cultivation, as highlighted in the outcome document 
of the special session of the General Assembly. That 
knowledge, together with continuous monitoring 
and impact assessment, is a prerequisite for the 
implementation of effective alternative development 
programmes. 
With a new branch of the Balkan route 
gaining in importance, the Caucasus needs 
to be monitored for a possible increase in 
heroin trafficking 
The increased attention generated by the massive 
flow of migrants and refugees through the Balkan 
route may have pushed traffickers to smuggle heroin 
through a new branch of the route via countries in 
the Caucasus. The international community and 
the countries affected need to increase vigilance in 
order to prevent trafficking from spreading and to 
ensure that trade agreements, while undoubtedly 
beneficial to the economy of the region, do not 
facilitate the trafficking of heroin. 
Addressing illicit crop  
cultivation and drug traf-
ficking can reduce the reach 
of some terrorist groups 
Although not all terrorist groups depend on drug 
profits, some do. Without the proceeds of drug pro-
duction and trafficking, which make up almost half 
of the Taliban’s annual income from all sources, the 
reach and impact of the Taliban would probably not 
be what it is today. In the case of terrorist groups 
and non-State armed groups heavily involved in 
drug production and/or trafficking, the fight against 
terrorism can only be effective if drug control is 
considered an integral part of the strategy. 
 Technological change,  
including trafficking over  
the darknet, requires a new 
generation of law enforcement 
interventions 
Organized crime groups are quick to adapt their 
modi operandi and exploit advances in technology, 
from the use of semi-submersible vessels, drones and 
modern telecommunications equipment for traf-
ficking to the use of the darknet for the purchase 
and sale of drugs. An effective response to these 
developments requires better equipped and trained 
police forces. The establishment of dedicated teams 
to conduct investigations into the darknet can help 
law enforcement agencies to develop highly special-
ized skills, but with continued technological 
advancement and the relevance of digital evidence 
to almost every crime, there is an urgent need to 
31
CONCLUSIONS AND POLICY IMPLICATIONS 1
mainstream online investigation and electronic evi-
dence collection capability across all law enforcement 
agencies. This approach will ensure that highly 
trained, specialized cyberinvestigators can focus on 
the most appropriate, high-risk, challenging and 
impactive cases. 
PEACE, JUSTICE
AND STRONG
INSTITUTIONS
Fighting drug trafficking as  
a fundamental factor in the 
achievement of Sustainable 
Development Goal 16;  
preventing organized crime 
groups diversifying their portfolios 
requires strategies that go beyond the 
reduction and elimination of single illicit 
markets 
Although they still represent between one fifth and 
one third of the total income from transnational 
organized crime, the importance of drugs in overall 
illicit activities is declining. Organized crime groups 
have become more agile in their structure and more 
versatile, moving opportunistically from one market 
to another and bypassing regulatory systems in order 
to make a profit. Addressing transnational organized 
crime therefore requires more effective and substan-
tial long-term investment in individuals and 
communities. Areas affected by organized crime 
need to find alternative social and economic solu-
tions that are supported by legitimate and transparent 
institutions and robust rule of law. 
Going after drug money as one of the 
most effective approaches to combating 
drug trafficking 
While the economic impact of drug proceeds and 
illicit financial flows may be too small to be really 
significant for the majority of countries, it can still 
have negative consequences for smaller economies, 
particularly in developing countries. Part of target 
16.4 of the Sustainable Development Goals is to 
significantly reduce illicit financial flows. Drug prof-
its are what drive traffickers, and identifying the 
flows related to those profits and the channels where 
they are invested and laundered can effectively coun-
teract them. Strengthening international cooperation 
in combating money-laundering also helps to reduce 
or eliminate the potential negative economic and 
social consequences from the outset.
$
Role of the United Nations 
Convention against  
Corruption in achieving 
target 16.5 of the  
Sustainable Development 
Goals (substantially reduce corruption and  
bribery in all their forms) and helping 
address the drug problem 
Corruption and drugs reinforce each other, with 
corruption facilitating the production of and 
trafficking in drugs, which, in turn, fuel corruption. 
Corruption occurs at all levels along the illicit drug 
supply chain, from production and trafficking to 
consumption, and affects a wide range of institutions: 
eradication teams, alternative development projects, 
law enforcement agencies, the criminal justice 
system and the health sector, as well as private 
companies, including chemical companies, 
pharmacies and transport companies. The United 
Nations Convention against Corruption provides 
the tools to break this vicious circle and its review 
mechanism can support countries in identifying 
practical steps to reduce corruption. Actions that 
have proved effective in reducing drug-related 
corruption include proper scrutiny of key personnel, 
anti-corruption training, the payment of a decent 
income to those vulnerable to corruption, rotation 
of officers in vulnerable units to avoid creating 
permanent links with organized crime groups, legal 
sanctions against corruption and the creation of an 
overall climate in which corruption is not tolerated, 
including systems to allow for the anonymous 
reporting of corruption and for witness protection. 
Strengthening the knowledge 
base of the drug problem by 
improving data, analysis and  
dissemination at the national, 
regional and international levels,  
including on the links between drugs  
and other issues 
The World Drug Report provides the best picture of 
the drug problem that can be assembled with the 
data and information available globally. The report 
provides ample evidence to guide the international 
community on key aspects of drug policy, but much 
remains unknown, even with regard to the basic 
indicators of drug use, particularly in Africa and 
Asia. Enhanced international cooperation to support 
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less developed countries in collecting data and shar-
ing information can greatly improve both regional 
and global understanding of the drug problem. With 
the continuing shifts and changes in the multiple 
facets of the drug problem, the timely global mon-
itoring of drug demand and supply has never been 
so crucial. While maintaining the coverage of basic 
drug issues, the international community also needs 
to respond to the calls contained in the outcome 
document of the special session of the General 
Assembly to collect data and undertake research on 
emerging issues such as NPS markets, illicit finan-
cial flows, the darknet and the links between drugs, 
terrorism, corruption and other forms of organized 
crime. 
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GLOSSARY
amphetamine-type stimulants — a group of sub-
stances composed of synthetic stimulants that were 
placed under international control in the Conven-
tion on Psychotropic Substances of 1971 and are 
from the group of substances called amphetamines, 
which includes amphetamine, methamphetamine, 
methcathinone and the “ecstasy”-group substances 
(3,4-methylenedioxymethamphetamine (MDMA) 
and its analogues).
amphetamines — a group of amphetamine-type 
stimulants that includes amphetamine and 
methamphetamine.
annual prevalence — the total number of people of 
a given age range who have used a given drug at 
least once in the past year, divided by the number 
of people of the given age range, and expressed as a 
percentage.
coca paste (or coca base) — an extract of the leaves 
of the coca bush. Purification of coca paste yields 
cocaine (base and hydrochloride).
“crack” cocaine — cocaine base obtained from 
cocaine hydrochloride through conversion processes 
to make it suitable for smoking.
cocaine salt — cocaine hydrochloride.
new psychoactive substances — substances of abuse, 
either in a pure form or a preparation, that are not 
controlled under the Single Convention on Narcotic 
Drugs of 1961 or the 1971 Convention, but that 
may pose a public health threat. In this context, the 
term “new” does not necessarily refer to new inven-
tions but to substances that have recently become 
available.
opiates — a subset of opioids comprising the various 
products derived from the opium poppy plant, 
including opium, morphine and heroin.
opioids — a generic term applied to alkaloids from 
opium poppy (opiates), their synthetic analogues 
(mainly prescription or pharmaceutical opioids) and 
compounds synthesized in the body.
problem drug users — people who engage in the 
high-risk consumption of drugs; for example, people 
who inject drugs, people who use drugs on a daily 
basis and/or people diagnosed with drug use disor-
ders (harmful use or drug dependence), based on 
clinical criteria as contained in the Diagnostic and 
Statistical Manual of Mental Disorders (fifth edi-
tion) of the American Psychiatric Association, or 
the International Classification of Diseases (tenth 
revision) of the World Health Organization. 
people who suffer from drug use disorders/people with 
drug use disorders — a subset of people who use 
drugs. People with drug use disorders need treat-
ment, health and social care and rehabilitation. 
Dependence is a drug use disorder. 
prevention of drug use and treatment of drug use dis-
orders — the aim of “prevention of drug use” is to 
prevent or delay the initiation of drug use, as well 
as the transition to drug use disorders. Once there 
is a drug use disorder, treatment, care and rehabili-
tation are needed.
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REGIONAL GROUPINGS  
• Central Asia and Transcaucasia: Armenia, 
Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, 
Tajikistan, Turkmenistan and Uzbekistan
• East and South-East Asia: Brunei Darussalam, 
Cambodia, China, Democratic People’s 
Republic of Korea, Indonesia, Japan, Lao 
People’s Democratic Republic, Malaysia, 
Mongolia, Myanmar, Philippines, Republic of 
Korea, Singapore, Thailand, Timor-Leste and 
Viet Nam 
• South-West Asia: Afghanistan, Iran (Islamic 
Republic of ) and Pakistan 
• Near and Middle East: Bahrain, Iraq, Israel, 
Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi 
Arabia, State of Palestine, Syrian Arab Republic, 
United Arab Emirates and Yemen
• South Asia: Bangladesh, Bhutan, India, 
Maldives, Nepal and Sri Lanka 
• Eastern Europe: Belarus, Republic of Moldova, 
Russian Federation and Ukraine
• South-Eastern Europe: Albania, Bosnia and 
Herzegovina, Bulgaria, Croatia, Montenegro, 
Romania, Serbia, the former Yugoslav Republic 
of Macedonia and Turkey
• Western and Central Europe: Andorra, Austria, 
Belgium, Cyprus, Czechia, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, 
Iceland, Ireland, Italy, Latvia, Liechtenstein, 
Lithuania, Luxembourg, Malta, Monaco, 
Netherlands, Norway, Poland, Portugal, San 
Marino, Slovakia, Slovenia, Spain, Sweden, 
Switzerland and United Kingdom of Great 
Britain and Northern Ireland
• Oceania: Australia, Fiji, Kiribati, Marshall 
Islands, Micronesia (Federated States of ), 
Nauru, New Zealand, Palau, Papua New 
Guinea, Samoa, Solomon Islands, Tonga, 
Tuvalu, Vanuatu and small island territories
The World Drug Report uses a number of regional 
and subregional designations. These are not official 
designations, and are defined as follows:
• East Africa: Burundi, Comoros, Djibouti, 
Eritrea, Ethiopia, Kenya, Madagascar, 
Mauritius, Rwanda, Seychelles, Somalia, 
Uganda and United Republic of Tanzania 
• North Africa: Algeria, Egypt, Libya, Morocco, 
South Sudan, Sudan and Tunisia
• Southern Africa: Angola, Botswana, Lesotho, 
Malawi, Mozambique, Namibia, South Africa, 
Swaziland, Zambia and Zimbabwe
• West and Central Africa: Benin, Burkina Faso, 
Cameroon, Cabo Verde, Central African 
Republic, Chad, Congo, Côte d’Ivoire, 
Democratic Republic of the Congo, Equatorial 
Guinea, Gabon, Gambia, Ghana, Guinea, 
Guinea-Bissau, Liberia, Mali, Mauritania, 
Niger, Nigeria, Sao Tome and Principe, Senegal, 
Sierra Leone and Togo 
• Caribbean: Antigua and Barbuda, Bahamas, 
Barbados, Bermuda, Cuba, Dominica, 
Dominican Republic, Grenada, Haiti, Jamaica, 
Saint Kitts and Nevis, Saint Lucia, Saint 
Vincent and the Grenadines and Trinidad and 
Tobago
• Central America: Belize, Costa Rica,  
El Salvador, Guatemala, Honduras, Nicaragua 
and Panama
• North America: Canada, Mexico and United 
States of America 
• South America: Argentina, Bolivia 
(Plurinational State of ), Brazil, Chile, 
Colombia, Ecuador, Guyana, Paraguay, Peru, 
Suriname, Uruguay and Venezuela (Bolivarian 
Republic of )
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To celebrate 20 years since its inception, the World Drug 
Report 2017 is presented in a new five-booklet format 
designed to improve reader friendliness while maintaining the 
wealth of information contained within. 
Booklet 1 summarizes the content of the four subsequent 
substantive booklets and presents policy implications drawn 
from their findings. Booklet 2 deals with the supply, use and 
health consequences of drugs. Booklet 3 focuses on the 
cultivation, production and consumption of the three 
plant-based drugs (cocaine, opiates and cannabis) and on the 
impact of new cannabis policies. Booklet 4 provides an 
extended analysis of the global synthetic drugs market and 
contains the bulk of the analysis for the triennial global 
synthetic drugs assessment. Finally, Booklet 5 contains a 
discussion on the nexus between the drug problem, organized 
crime, illicit financial flows, corruption and terrorism.
 
Enhanced by this new format, the World Drug Report 2017 is, 
as ever, aimed at improving the understanding of the world 
drug problem and contributing towards fostering greater 
international cooperation for countering its impact on health 
and security.
The statistical annex is published on the UNODC website: 
www.unodc.org/wdr/2017
